The growth timeline of a Korean stem cell medical group
Quick answer
EHL Bio began with a bio research institute founded in 2012, then built its own GMP cell-manufacturing centre, earned a Japanese CPC licence, grew a network of roughly 100 partner hospitals in Korea and 50 abroad, and pushed several cell drugs into clinical trials.
EHL Bio started from research on adipose-derived mesenchymal stem cells, a source harvested from the patient themselves with no embryonic material involved. Setting up a corporate research institute back in 2012 meant the company accumulated its own culture know-how instead of licensing it in.
The next step was investing in its own GMP centre — a hard requirement for developing regulated cell drugs rather than simply offering cell injections. The facility supports thousands of culture lots a year and supplies both the research programme and the partner hospital network.
Winning a CPC licence from Japan's Ministry of Health, Labour and Welfare was a milestone: it means the manufacturing process was inspected by another country's regulator rather than self-certified. Overseas patients can use that as a concrete benchmark when comparing providers.
Both. The group combines a treating hospital, a bio research company and a GMP cell-manufacturing centre under one organisation.
Yes — consistent cell culture depends on years of accumulated process data and traceability systems, not just new equipment.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: EHL hospital & lab